Repligen (RGEN) Total Non-Current Liabilities (2011 - 2026)
Repligen's (RGEN) quarterly Total Non-Current Liabilities came in at $821.1 million in Q2 2026, up 14.53% year-over-year from $716.9 million in Q2 2025, and up 1.55% quarter-over-quarter from $808.6 million in Q1 2026.
Analysis
Repligen (RGEN) Total Non-Current Liabilities (2011 - 2026) Analysis & Trends
Repligen (RGEN) has reported Total Non-Current Liabilities for 16 consecutive years, with $821.1 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 14.53% year-over-year to $821.1 million in Q2 2026; TTM through Jun 2026 was $821.1 million, a 14.53% increase from a year earlier, with the FY2025 full-year figure at $707.7 million, down 3.07% from the prior year.
- Total Non-Current Liabilities was $821.1 million for Q2 2026 at Repligen, up from $808.6 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $821.1 million in Q2 2026 and troughed at $170.1 million in Q3 2023.
- A 5-year average of $525.4 million and a median of $706.1 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities decreased 21.54% in 2023 and soared 314.93% in 2024, its largest moves.
- Over 5 years, Total Non-Current Liabilities stood at $216.7 million in 2022, then surged by 223.67% to $701.4 million in 2023, then grew by 4.1% to $730.2 million in 2024, then fell by 3.07% to $707.7 million in 2025, then increased by 16.01% to $821.1 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $821.1 million (Q2 2026), $808.6 million (Q1 2026), and $707.7 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 223.99 Bn | 219.93 Bn | 8.34 Bn | 55.95 Bn |
| 2 | Danaher | 141.56 Bn | 137.22 Bn | 3.61 Bn | 33.25 Bn |
| 3 | Agilent Technologies | 40.36 Bn | 38.60 Bn | 1.04 Bn | 6.06 Bn |
| 4 | Illumina | 30.41 Bn | 29.24 Bn | 770.00 Mn | 3.52 Bn |
| 5 | Revvity | 13.50 Bn | 12.48 Bn | 416.87 Mn | 4.05 Bn |
| 6 | Bio-Techne | 11.25 Bn | 10.98 Bn | 211.39 Mn | 457.16 Mn |
| 7 | Bio-Rad Laboratories | 9.88 Bn | 8.26 Bn | 345.80 Mn | 2.88 Bn |
| 8 | Repligen | 9.29 Bn | 8.28 Bn | 110.04 Mn | 821.06 Mn |
| 9 | 10x Genomics | 8.62 Bn | 8.06 Bn | 112.50 Mn | 197.96 Mn |
| 10 | Bruker | 8.16 Bn | 7.94 Bn | 416.00 Mn | 3.06 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 821.06 Mn |
| Mar 31, 2026 | 808.55 Mn |
| Dec 31, 2025 | 707.74 Mn |
| Sep 30, 2025 | 709.49 Mn |
| Jun 30, 2025 | 716.87 Mn |
| Mar 31, 2025 | 714.66 Mn |
| Dec 31, 2024 | 730.16 Mn |
| Sep 30, 2024 | 705.59 Mn |
| Jun 30, 2024 | 706.76 Mn |
| Mar 31, 2024 | 706.55 Mn |
| Dec 31, 2023 | 701.40 Mn |
| Sep 30, 2023 | 170.05 Mn |
| Jun 30, 2023 | 211.85 Mn |
| Mar 31, 2023 | 204.67 Mn |
| Dec 31, 2022 | 216.70 Mn |
| Sep 30, 2022 | 216.73 Mn |
| Jun 30, 2022 | 216.03 Mn |
| Mar 31, 2022 | 193.09 Mn |
| Dec 31, 2021 | 233.03 Mn |
| Sep 30, 2021 | 176.69 Mn |